These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 7141787

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Anti-oxidant status in relation to lipoproteins, leptin and pro-inflammatory cytokines in children with steroid-sensitive nephrotic syndrome.
    Ece A, Atamer Y, Gürkan F, Bilici M, Koçyiğit Y.
    Nephrology (Carlton); 2004 Dec; 9(6):366-73. PubMed ID: 15663638
    [Abstract] [Full Text] [Related]

  • 24. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.
    Schalm SW, Summerskill WH, Go VL.
    Gastroenterology; 1977 May; 72(5 Pt 1):910-3. PubMed ID: 849821
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Plasma protein thiols and total antioxidant power in pediatric nephrotic syndrome.
    Karthikeyan K, Sinha I, Prabhu K, Bhaskaranand N, Rao A.
    Nephron Clin Pract; 2008 May; 110(1):c10-4. PubMed ID: 18663332
    [Abstract] [Full Text] [Related]

  • 28. Pharmacokinetics of furosemide urinary elimination by nephrotic children.
    Prandota J.
    Pediatr Res; 1983 Feb; 17(2):141-7. PubMed ID: 6828331
    [Abstract] [Full Text] [Related]

  • 29. Reversible metabolism and pharmacokinetics: application to prednisone-prednisolone.
    Wagner JG, DiSanto AR, Gillespie WR, Albert KS.
    Res Commun Chem Pathol Pharmacol; 1981 Jun; 32(3):387-405. PubMed ID: 7268190
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Dynamics of bone biochemical markers in nephrotic children treated with prednisone and metabolites of vitamin D].
    Wojnar J, Roszkowska-Blaim M, Pańczyk-Tomaszewska M.
    Przegl Lek; 2007 Jun; 64(9):552-8. PubMed ID: 18510075
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function.
    Frey BM, Walker C, Frey FJ, de Weck AL.
    J Immunol; 1984 Nov; 133(5):2479-87. PubMed ID: 6237151
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [The effect of treatment methods on frequency of relapse in nephrotic syndrome in children].
    Goszczyk A, Jung A, Bochniewska V, Straz-Zebrowska E.
    Pol Merkur Lekarski; 2000 Sep; 9 Suppl 1():25-6. PubMed ID: 11081338
    [Abstract] [Full Text] [Related]

  • 38. A pharmacokinetic comparison of two oral liquid glucocorticoid formulations.
    Kamada AK, Wiener MB, LaVallee NM, Scott MB, Selner JC, Szefler SJ.
    Pharmacotherapy; 1997 Sep; 17(2):353-6. PubMed ID: 9085328
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.